Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

University of Alabama at Birmingham2,000 enrolled

Overview

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Lymphoma Hemophagocytic Lymphohistiocytoses

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with lymphoma that are fulfilling at least one of the following: A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL) Exclusion Criteria: * Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas) * Patients with incomplete treatment and response documentation

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

RECRUITING

Outcomes

Primary Outcomes

To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+

The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.

Time frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis

Central Contacts

Gaurav Goyal, MD

CONTACT

205-934-1816 ggoyal@uabmc.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.